Seven years of follow up of trabecular bone score,bone mineral density,body composition and quality of life in adults with growth hormone deficiency treated with rhGH replacement in a single center

Abstract

Background:

Adult growth hormone deficiency (AGHD) is characterized by impaired physical activity, diminished quality of life (QoL), weight and fat mass gain, decreased muscle mass and decreased bone mineral density (BMD). The aim of this study was to evaluate the effects of long-term treatment (7 years) with recombinant human growth hormone (rhGH) on metabolic parameters, body composition (BC), BMD, bone microarchitecture and QoL.

Patients and Methods:

In this prospective study, BMD and BC were assessed by dual-energy X-ray absorptiometry (DXA). Bone microarchitecture was assessed with the trabecular bone score (TBS). The QoL-AGHDA test was used to assess QoL.

Results:

A total of 18 AGHD patients (mean age, 37.39 ± 12.42) were included. Body weight and body mass index (BMI) showed a significant increase after 7 years (p = 0.03 and p = 0.001, respectively). There was a significant tendency of body fat mass (BFM) (p = 0.028) and lean body mass (LBM) (p = 0.005) to increase during the 7 years of rhGH treatment. There was a significant increase in lumbar spine (LS) BMD (p = 0.01). TBS showed a nonsignificant decrease after 7 years of treatment, with a change of -0.86% ± 1.95. QoL showed a large and significant improvement (p = 0.02).

Conclusion:

Long-term rhGH treatment in AGHD patients induces a large and sustained improvement in QoL. Metabolic effects are variable with an increase in LBM as well as in BMI and BFM. There is a positive effect on BMD based on the increase in LS BMD, which stabilizes during long-term therapy and is not associated with a similar increase in bone microarchitecture.

Keywords

Adult growth hormone deficiency bone mineral density trabecular bone score

Introduction

The syndrome of adult growth hormone deficiency (AGHD) is characterized by the variable presence of impaired physical activity, diminished quality of life (QoL), increased fat mass, decreased muscle mass and decreased bone mineral density (BMD) [De Boer et al. 1995]. Benefits of treatment with recombinant human growth hormone (rhGH) in AGHD patients have been reported in BMD, body composition (BC) and QoL [Hazem et al. 2012].

Short-term rhGH replacement in AGHD patients has shown an anabolic effect, after an initial BMD decline [Molitch et al. 2011]. After the first 12 months of rhGH treatment some authors reported no improvement and even a reduced BMD [Holmes et al. 1994; Appelman-Dijkstra et al. 2013]. Other studies reported that 18–24 months of GH replacement were necessary to get an increase in BMD [Biller et al. 2000; Bex et al. 2002]. Results from a 15-year study have shown a sustained increase in lumbar spine (LS) BMD with a peak of femoral neck (FN) BMD at 7 years and a following decrease towards baseline values [Elbornsson et al. 2012].

It has recently been reported that in GH-deficient mice, rhGH treatment fully restored bone microarchitecture, with bone partially recovering its mechanical properties [Kristensen et al. 2012]. In humans, the only noninvasive technique to study bone trabecular microarchitecture is the Trabecular Bone Score (TBS), which evaluates pixel gray-level variations in the Dual-energy X-ray absorptiometry (DXA) image [Silva et al. 2013]. TBS has been used to evaluate the impact of short-term rhGH replacement in AGHD patients on bone microarchitecture [Kužma et al. 2014]. Authors found an increase in the TBS score, suggesting a positive effect of rhGH on bone quality. To our knowledge, there are no available studies about the effect of long term replacement on TBS.

Regarding BC, rhGH therapy in ADGH patients has favorable effects, reducing body fat mass (BFM) and increasing lean body mass (LBM) in short and long-term studies [Appelman-Dijkstra et al. 2013; Bravenboer et al. 1996]. It has been found that rhGH replacement improves QoL, but studies have shown a high degree of variability [Reed et al. 2013; Diez and Cordido, 2014]. QoL improvement has neither been observed in all patients nor in all psychological dimensions [Koltowska_Haggstrom et al. 2009; Moock et al. 2009; Spielhagen et al. 2011]. As AGHD is a chronic disease in which GH replacement is recommended to continue for years, long-term studies are mandatory.

The aim of this prospective, open-label study was to evaluate the effect of 7 years therapy with rhGH on BMD, BC, TBS and QoL in a group of patients with AGHD from a single center, followed up in our unit.

Material and methods

Patients

A total of 25 AGHD White patients were invited to participate in the study. A total of 18 of them (9 men and 9 women), voluntarily agreed to participate in this long-term study and signed the consent form. All of them were diagnosed with untreated AGHD, after the age of 18 years, due to a hypothalamic-pituitary disease (seven pituitary adenomas, five craniopharyngiomas, two postoperative, one postirradiation and three idiopathic). Diagnosis of AGHD was confirmed by using an insulin tolerance test (gold standard test) and glucagon test, according to the National Health Service in Spain, which requires two tests. A serum GH value < 5 µg/l at any time during the testing was the criterion for the presence of GHD. All patients also had concomitant pituitary hormone deficits and were receiving adequate stable pituitary hormone replacement therapy, when necessary. Patients with acromegaly or Cushing’s disease were excluded from the study to avoid interference with the BMD value at baseline (because of an excess of GH or cortisol effect).

AGHD patients were treated with rhGH (Genotropin; Pfizer Inc., New York, NY, USA) subcutaneously once a day. They were monitored quarterly during dose titration and then semiannually. Dose titration was based on insulin-like growth factor-1(IGF-1) level with the aim of normalizing the IGF-1 standard deviation (SD) score, clinical response and side effects. When required, if patients had any other pituitary hormonal deficiency, they received adequate and stable therapy and were monitored at every visit. None of the patients died during the study.

Study design

This study was performed in our Endocrinology Unit, Madrid, Spain, between 2001 and 2012. The Ethics Committee of our Hospital approved the study and informed consent was obtained from all the patients. All patients were evaluated at baseline (without treatment) and then at years 1, 2, 3, 5, and 7 of the treatment. The following parameters were assessed at every visit: body mass index (BMI), BMD, BC, TBS and QoL. BMI was calculated as the weight in kilograms divided by the height in meters squared. Also, fasting blood samples were obtained and analyzed for IGF-1. TBS was assessed from previously collected DXA spine images.

Bone mineral density, trabecular bone score and body composition

BMD was assessed by DXA, (densitometer QDR 4500, Hologic, Waltham MA, USA) at LS and FN and expressed in g/cm². Precision error was less than 1.5%. Values were expressed as absolute values (g/cm2) or T-score, which is the difference of SDs from the sex-matched young healthy subjects. A Spanish Caucasian reference population of the same age and sex was used for calculations [Díaz Curiel et al. 1997]. Diagnoses of osteoporosis and osteopenia followed World Health Organization (WHO) criteria (osteoporosis ⩽ -2.5 SD, osteopenia -1 to -2.49 SD and normal ⩾ -1 SD) [World Health Organization 1998]. BC including BFM and LBM was also assessed by DXA in the same densitometer.

TBS measurements were performed applying retrospectively the TBS iNsight2.0 software (Med-Imaps, Switzerland) to DXA exams. TBS exams were performed by the same author. Lumbar TBS was calculated as the mean value of individual measurements for vertebrae L1–L4. TBS ⩾ 1.35 is considered normal; between 1.20–1.35 is consistent with partially degraded microarchitecture, and ⩽ 1.20 with degraded microarchitecture [Silva et al. 2013].

Quality of life

QoL was assessed using the QoL-AGHDA, a questionnaire designed specifically to evaluate quality of life in adults with GHD. It was validated in a study performed with 356 AGHD patients and 963 patients (reference population) in 37 Spanish hospitals [Badia et al. 1998]. The questionnaire consists of 25 unidimensional items measuring QoL. All the items in the QoL-AGHDA are expressed as unsatisfied needs. A score of 0 indicates absence of problems, and a score of 1 or more indicates the presence of a problem. A high score represents poorer QoL.

Biochemical analysis

Serum samples for biochemical analyses were obtained between 8 and 9 a.m. after overnight fast and immediately kept frozen at -70ºC. Serum levels of IGF-1 were quantified using an automated chemiluminescent immunoassay by Immulite® 2000 Immunoassay System (Siemens, Germany). ImmuliteR IGF-1 is a two-site, solid-phase, chemiluminescent enzyme immunometric assay and is standardized according to the WHO’s 2nd IS 87/518 [Bristow et al. 1990]. Individual IGF-1 values were compared with age and sex values from a reference population.

Statistical analysis

Data analysis was performed with SPPS (version 21.0; IBM, Armonk, NY, USA). Descriptive results are presented as the mean and SD. A normally distributed population was confirmed with the Shapiro–Wilks test. Statistical analysis was performed using the Student’s t-test between baseline and 7-year measurements. We studied the evolution (from baseline to 7 years of treatment) applying MANOVA analysis for repeated measures. Correlations were calculated using Pearson’s test. A p-value < 0.05 was defined as the level of significance.

Results

Baseline characteristics of AGHD patients are shown in Table 1.

Table 1.

Baseline characteristics of AGHD patients.

Characteristic	All patients (n = 18)	Males (n = 9)	Females (n = 9)
Age (years)	37.39 ± 12.42	40.22 ± 12.76	34.56 ± 12.11
Body weight (kg)	78.6 ± 20.2	81.5 ± 21.1	76.0 ± 20.2
Body height (cm)	162.5 ± 10.0	169.4 ± 11.3	156.4 ± 5.9
BMI (kg/m²)	29.81 ± 7.70	28.23 ± 6.40	31.22 ± 8.83
Body fat mass (kg)	27.77 ± 12.15	24.25 ± 13.41	30.89 ± 10.69
Lean body mass (kg)	47.31 ± 11.67	53.77 ± 11.04	41.57 ± 9.32
Lumbar spine BMD (g/cm²)	0.89 ± 0.12	0.95 ± 0.12	0.84 ± 0.10
Lumbar spine T-score	−1.60 ± 1.00	−1.14 ± 1.00	−2.02 ± 0.85
Femoral neck BMD (g/cm²)	0.83 ± 0. 16	0.88 ± 0.19	0.78 ± 0.13
Femoral neck T-score	−0.96 ± 1.56	−0.61 ± 1.98	−1.28 ± 1.11
Trabecular bone score	1.36 ± 0.11	1.37 ± 0.13	1.34 ± 0.97
IGF-1 (ng/ml)	76.88 ± 43.32	89.88 ± 51.11	65.33 ± 33.87

AGHD, adult growth hormone deficiency; BMD, bone mineral density; BMI, body mass index; IGF-1, insulin-like growth factor-1.

Serum IGF-1 concentration

IGF-1 increased significantly, compared to the baseline, until the end of the study (p = 0.003). A MANOVA test showed a significant tendency to increase (p < 0.001) over the 7 years of rhGH replacement. Similar findings were found in both genders. No correlation was found between IGF-1 and QoL or TBS.

BMI and BC

Baseline BMI was in the overweight range at baseline and increased significantly to 32.07 ± 8.30 kg/m² after 7 years (p = 0.001) (Table 2). Both male (p = 0.47) and female groups (p = 0.02) showed a significant increase in BMI at the end of the study. A MANOVA test showed no significant evolution in BMI. A MANOVA test showed a significant tendency of BFM (p = 0.028) and LBM (p = 0.005) to increase during the 7 years of rhGH treatment (Table 2). Changes in LBM showed a sustained increase in the total group, from 47.31 ± 11.67 kg at baseline to 52.02 ± 12.41 kg at the end of the study (Figure 1). The female group had similar results with a significant sustained increase throughout the study (p = 0.04). BFM showed a nonsignificant increase from 27.77 ± 12.15 kg at baseline to 31.85 ± 13.93 kg after 7 years of treatment (Figure 2).

Table 2.

Evolution of BMI, BFM, LBM, LS BMD, FN BMD and TBS during the study.

Characteristic	Baseline	1^st year	2^nd year	3^rd year	5^th year	7^th year	p-value (MANOVA)
BMI (kg/m²)	29.81 ± 7.70	30.15 ± 7.97	30.39 ± 7.36	31.63 ± 8.78	31.48 ± 9.08	32.07 ± 8.30	n.s.
BFM (kg)	27.77 ± 12.15	27.19 ± 12.09	28.07 ± 12.81	26.32 ± 13.15	29.38 ± 13.69	31.85 ± 13.93	0.028
LBM (kg)	47.31 ± 11.67	48.74 ± 11.42	51.74 ± 11.30	52.29 ± 13.21	52.43 ± 12.22	52.02 ± 12.41	0.005
Lumbar spine BMD (g/cm²)	0.89 ± 0.12	0.89 ± 0.11	0.91 ± 0.12	0.92 ± 0.14	0.90 ± 0.15	0.94 ± 0.16	n.s.
Femoral neck BMD (g/cm²)	0.83 ± 0. 16	0.84 ± 0.17	0.83 ± 0.13	0.84 ± 0.13	0.83 ± 0.15	0.84 ± 0.14	n.s
TBS	1.36 ± 0.11	1.34 ± 0.13	1.34 ± 0.11	1.35 ± 0.13	1.32 ± 0.16	1.32 ± 0.10	n.s.

BFM, body fat mass; BMI, body mass index; FN BMD, femoral neck bone mineral density; LBM, lean body mass; LS BMD, lumbar spine bone mineral density; n.s., not significant; TBS, trabecular bone score.

Figure 1.

Lean body mass change after 7 years of rhGH therapy (MANOVA, p = 0.005).

Figure 2.

Body fat mass change after 7 years of rhGH therapy (MANOVA, p = 0.028).

BMD and TBS

Baseline LS T-scores were in the osteopenia range in the total, male and female groups and FN T-scores, normal in the total and male group, but in the osteopenia range in the female group. LS BMD increased throughout the study, and after 7 years of rhGH treatment there was a significant increase compared to baseline (p = 0.01), with a percentage change of +4.73% ± 2.91. Male and female groups showed no significant differences. During the 7 years of rhGH treatment, FN BMD values tended towards stabilization, without significant improvement in the total, male and female group. A MANOVA test showed no significant tendency in LS and FN BMD (Table 2).

Baseline TBS (1.36 ± 0.11) was in the upper normal range (1.35) in the total, female and male group. TBS showed a nonsignificant decrease after 7 years of treatment (1.32 ± 0.10). Gender differentiated groups showed similar results. No significant correlation was found between TBS and BC or BMD values. A MANOVA test showed no significant tendency over the 7 years of treatment.

QoL

The baseline QoL-AGHDA score was 11.94 ± 6.70. After the first year of rhGH treatment the score showed a large improvement, which lasted until year 7 of treatment (p = 0.02) (Figure 3). A MANOVA test showed a significant temporal tendency (p = 0.03) over the years of the study in the total group, but not in the male and female subgroups. No correlations were found between improvement in QoL-AGHDA score and increase in BLM or in lumbar spine BMD.

Figure 3.

QoL-AGHDA score temporal evolution after 7 years of rhGH treatment (MANOVA, p < 0.01).

Discussion

AGHD is a syndrome in which structural pituitary disease or cranial irradiation are recognized in the etiology and therefore, usually occurs in the context of additional features of hypopituitarism. The fact that GH replacement therapy may favorably alter these clinical features provides considerable surrogate evidence for GH deficiency as a major causal factor [Littley et al. 1988].

Most of the recent studies and systematic reviews have reported an increase in LBM, and a decrease in BFM with rhGH long-term supplementation [Gotherstrom et al. 2007; Gibney et al. 1999]. We observed a sustained and significant increase in LBM over the 7 years of treatment. However, our study shows a significant tendency of BFM to increase over the years of treatment. We cannot find a reason to justify the increase in BFM and this could be related to the small population of our study. A previous meta-analysis reported a significant and consistent reduction in weight after long-term rhGH supplementation [Hazem et al. 2012]. On the contrary, a more recent systematic review has shown weight gain [Kristensen et al. 2012; Gotherstrom et al. 2007]. In agreement with this, our results show a significant increase in body weight at the end of the study, compared to the baseline. The mean baseline BMI of our patients was in the range of overweight, and significantly increased after 7 years of treatment, reaching the obese range. Our results support that metabolic risk is increased in AGHD patients, irrespective of long-term substitution with recombinant rhGH [Van der Klaauw et al. 2007].

AGHD is associated with decreased BMD and increased fracture risk [Tritos and Biller, 2009]. In our group, LS T-score baseline was in the osteopenia range for the total group and the male and female subgroups, which highlights the BMD decrease in AGHD patients. An initial transient decrease in BMD had been previously described in the first year of treatment [Tritos and Biller, 2009] but in our results neither LS nor FN BMD showed this decline during the first year of treatment. Several studies reported increase in BMD mainly in LS, after rhGH treatment [Snyder et al. 2007; Appelman-Dijkstra et al. 2014]. Mean LS BMD of our patients was significantly above baseline level after 7 years of rhGH therapy. FN BMD increase has also been reported to a smaller extent than LS BMD [Appelman-Dijkstra et al. 2013]. In our group, FN BMD showed no increase above baseline. A recent article has proposed a decrease and another one a stabilization of FN BMD values during 10–15 years of rhGH treatment [Elbornsson et al. 2012; Appelman_Dijkstra et al. 2014], which is consistent with our results. FN (predominantly cortical bone) may respond less to GH with time than with lumbar spine (rich in trabecular bone). During the 7 years of follow up no fracture was registered, although this was not evaluable given the short number of patients.

At baseline our patients showed mean TBS in the normal range, which, decreased nonsignificantly after 7 years of treatment. In short-term AGHD treated patients, Kužma and colleagues reported a significant increase in TBS after 2 years of replacement, but this increase did not reach normal values and was lower than the increase in BMD [Kužma et al. 2014]. In our study, however, baseline TBS was normal and 2 years after rhGH supplementation there was just a nonsignificant decrease in TBS. Therefore our study does not support a significant positive effect on bone microarchitecture in these patients. IGF-1 is considered to be a positive predictor of cortical bone microarchitecture [Bredella et al. 2012]; nevertheless, in our group, the progressive improvement in IGF-1 values showed no correlation with TBS.

Several tools have been used to assess QoL in AGHD patients. The QoL-AGHDA is a disease-specific QoL assessment questionnaire which has been validated for AGHD patients in Spain [McKenna et al. 1999]. Regarding QoL, KIMS database studies showed improvement within the first year of treatment and subsequent progress towards normalization [Spielhagen et al. 2011]. In our experience, the Spanish version has proven good reliability, internal consistency and construct validity [Sanmarti et al. 1999]. Similar findings in another long-term treated Spanish AGHD population were reported by Cabo and colleagues [Cabo et al. 2011]. Likewise, our results show low health-related QoL at baseline and a large and significant improvement after the first year of treatment, which continues to improve until the end of the study.

The strength of this study is that it provides information on many aspects of the effect of long-term rhGH replacement. Only well characterized AGHD patients were included in the study and none of them discontinued rhGH therapy or stopped the monitoring during the 7 years. Likewise, the study provides bone microarchitecture information, something which, to our knowledge, had never been studied in long-term AGHD treated patients. This study has some limitations like the small population, which limits the statistical power of the study and the lack of a control group, due to ethical reasons.

In conclusion, we have observed that 7 years of rhGH treatment in AGHD patients induces a large and sustained improvement in QoL. Metabolic effects are variable with an increase in LBM as well as in BMI and BFM. There is a positive effect on BMD based on the increase in LS BMD, which stabilizes during long-term therapy and is not associated with a similar increase in bone microarchitecture.

Footnotes

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

Appelman-Dijkstra

Claessen

Hamdy

Pereira

Biermasz

(2014) Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with Growth Hormone Deficiency (GHD): The Leiden Cohort Study. Clin Endocrinol 81: 727–735.

Appelman-Dijkstra

Claessen

Roelfsema

Pereira

Biermasz

(2013) Longterm effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. Eur J Endocrinol 169: R1–14.

Badia

Lucas

Sanmartí

Roset

Ulied

(1998) One-year follow up of quality of life in adults with untreated growth hormone deficiency. Clin Endocrinol (Oxf) 49: 765–771.

Bex

Abs

Maiter

Beckers

Lamberigts

Bouillon

(2002) The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J Bone Miner Res 17: 1081–1094.

Biller

Sesmilo

Baum

Hayden

Schoenfeld

Klibanski

(2000) Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab 85: 970–976.

Bravenboer

Holzmann

de Boer

Blok

Lips

(1996) Histomorphometric analysis of bone mass and bone metabolism in growth hormone deficient adult men. Bone 18: 551–557.

Bredella

Lin

Gerweck

Landa

Thomas

Torriani

. (2012) Determinants of bone microarchitecture and mechanical properties in obese men. J Clin Endocrinol Metab 97: 4115–4122.

Bristow

Gooding

Das

(1990) The international reference reagent for insulin like growth factor-I. J Endocrinol 125: 191–197.

Cabo

Lecube

Barrios

Mesa

(2011) Long term treatment with growth hormone deficiency in adults. Med Clin (Barc) 136: 659.

10.

De Boer

Blok

Van der Veen

(1995) Clinical aspects of growth hormone deficiency in adults. Endocr Rev 16: 63–86.

11.

Diaz Curiel

Carrasco de la Pena

Honorato Perez

Perez Cano

Rapado

Ruiz Martinez

(1997) Study of bone mineral density in lumbar spine and femoral neck in a Spanish population. Multicentre research project on osteoporosis. Osteoporos Int 7: 59–64.

12.

Diez

Cordido

(2014) Benefits and risks of growth hormone in adults with growth hormone deficiency. Med Clin (Barc) 143: 354–359.

13.

Elbornsson

Gotherstrom

Bosaus

Bengtsson

Johannsson

Svensson

(2012) Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol 166: 787–795.

14.

Gibney

Wallace

Spinks

Schnorr

Ranicar

Cuneo

. (1999) The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 84: 2596–2602.

15.

Gotherstrom

Bengtsson

Bosaeus

Johannsson

Svensson

(2007) A 10-year prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab 92: 1442–1445.

16.

Hazem

Elamin

Bancos

Malaga

Prutsky

Domecq

. (2012) Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. Eur J Endocrinol 166: 13–20.

17.

Holmes

Economou

Whitehouse

Adams

Shalet

(1994) Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 78: 669–674.

18.

Koltowska-Haggstrom

Mattsson

Shalet

(2009) Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. Eur J Endocrinol 161: S51–64.

19.

Kristensen

Hallgrimsson

Morck

Boyd

(2012) Microarchitecture, but not bone mechanical properties, is rescued with growth hormone treatment in a mouse model of growth hormone deficiency. Int J Endocrinol 2012: 294965.

20.

Kužma

Kužmova

Zelinkova

Killinger

Vaňuga

Lazurova . (2014) Impact of the growth hormone replacement on bone status in growth hormone deficient adults. Growth Horm IGF Res 24: 22–28.

21.

Littley

Shalet

Beardwell

Ahmed

Applegate

Sutton

(1988) Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med 262: 145–160.

22.

McKenna

Doward

Alonso

Kohlmann

Niero

Prieto

. (1999) The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 8: 373–383.

23.

Ministerio de Sanidad y Consumo. (2014) Criterios para la utilización racional de la hormona de crecimiento en adultos. Madrid: Ministerio de Sanidad y Consumo. Available at: http://www.msssi.gob.es/profesionales/farmacia/pdf/CriteriosHCAdultos.pdf

24.

Molitch

Clemmons

Malozowski

Merriam

Vance

(2011) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96: 1587–1609.

25.

Moock

Albrecht

Friedrich

Volzke

Nauck

Koltowska-Haggstrom

. (2009) Health-related quality of life and IGF- 1 in GH-deficient adult patients on GH replacement therapy: analysis of the German KIMS data and the study of health in Pomerania. Eur J Endocrinol 160: 17–24.

26.

Reed

Merriam

Kargi

(2013) Adult growth hormone deficiency – benefits, side effects, and risks of growth hormone replacement. Front Endocrinol (Lausanne) 4: 64.

27.

Sanmarti

Lucas

Hawkins

Webb

Ulied

(1999) Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA study). Socioeconomic impact and health status. Eur J Endocrinol 141: 481–489.

28.

Silva

Boutroy

Zhang

McMahon

Zhou

Wang

. (2013) Trabecular bone score (TBS). A novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 98: 1963–1970.

29.

Snyder

Biller

Zagar

Jackson

Arafah

Nippoldt

. (2007) Effect of growth hormone replacement on BMD in adult-onset growth hormone deficiency. J Bone Miner Res 22: 762–770.

30.

Spielhagen

Schwahn

Moller

Friedrich

Kohlmann

Moock

. (2011) The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database. Growth Horm IGF Res 21: 1–10, 18.

31.

Tritos

Biller

(2009) Growth hormone and bone. Curr Opin Endocrinol Diabetes Obes 16: 415–422.

32.

Van der Klaauw

Biermasz

Feskens

Bos

Smit

Roelfsema

. (2007) The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur J Endocrinol 156: 455–462.

33.

World Health Organization Scientific Group Research on Menopause (1998) WHO Technical Service Report Series 670. WHO Geneva.